Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines (NCT07421544) | Clinical Trial Compass
Not Yet RecruitingPhase 4
Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines
United States100 participantsStarted 2026-03-01
Plain-language summary
Clinical trial to assess the real-world effectiveness of Obagi® Saypha® MagIQ™ Injectable Hyaluronic Acid (HA) gel for the treatment of mild-to-moderate facial aging, including volume loss, fine lines, and skin laxity, following treatment administered using routine clinical injection techniques over the course of 60 days.
Who can participate
Age range30 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adult subjects aged 30 to 75 years at the time of screening/baseline.
✓. Fitzpatrick skin types I-VI.
✓. Investigator classification of the subject as having mild-to-moderate facial aging in at least one (≥1) facial areas, defined as meeting the following scale criteria at screening/baseline:
✓. Willing and able to comply with all study requirements, including scheduled visits, treatment protocol, and follow-up assessments.
✓. Willing and able to provide written informed consent form and photography release for research, publication, and/or commercial use.
✓. In good general health as determined by the investigator based on medical history and clinical judgment.
✓. Willing to maintain the study-specified skincare regimen and refrain from initiating new topical or procedural facial treatments during the study period.
✓. For subjects of childbearing potential, a negative urine pregnancy test at screening/baseline and at all subsequent visits, as applicable.
Exclusion criteria
✕. Prior use of injectable treatments to the face within the past 12 months, including HA fillers and biostimulator injectables, i.e. calcium hydroxyapatite, poly-L-lactic acid (e.g., Sculptra, Radiesse), platelet-rich plasma (PRP), platelet-rich fibrin (PRF) Any facial surgical procedure (e.g., facelift, facial implants) within the past 12 months.
✕. Use of neuromodulators (e.g., botulinum toxin) to the face or neck within 6 months prior to study enrollment or at any time during the study period.
What they're measuring
1
Physician Global Aesthetic Improvement Scale (PGAIS)
✕. Use of dermal fillers of any kind during the study period.
✕. Use of at-home energy-based devices intended for rejuvenation or fibroblastic/collagen stimulation within 30 days prior to treatment and during the study period.
✕. Use of systemic retinoids (e.g., isotretinoin) within 3 months prior to enrollment
✕. Active infection, open wounds, or inflammatory dermatoses (e.g., eczema, psoriasis, dermatitis) in the treatment area.
✕. Plants to become pregnant during the study period, or current breastfeeding.
✕. Known allergy or hypersensitivity to lidocaine, tetracaine, or other local anesthetics.